BOSTON MILLENNIA PARTNERS
BOSTON MILLENNIA PARTNERS is a Seed, Series A, Series B, Series C+ and angel fund in the US and Europe writing $250K–$3M checks into Enterprise, Healthcare, life-sciences, business-services, information-technology and healthcare-tech.
- Stages
- Seed, Series A, Series B, Series C+, angel
- Sectors
- Enterprise, Healthcare, life-sciences, business-services, information-technology, healthcare-tech
- Check size
- $250K–$3M
- Invests in
- US-wide, Europe
- Actively investing
- Yes
- Founded
- 1997
- Assets under management
- $700M+
- Website
- bostonmillenniapartners.com
Thesis
Boston Millennia Partners (BMP) is a growth equity firm based in Boston, MA, established in 1997. They focus on the healthcare, life sciences, business services, and information technology sectors, managing over $700 million in AUM. BMP's strategy involves providing private equity financing to high-growth companies, often using strategic acquisitions to build scale around a core company, particularly in fragmented, evolving markets. They seek companies with proven technologies, existing customers, and products/services, with revenues between $1 million and $20 million and enterprise values under $50 million. BMP invests in early and growth-stage businesses, including Seed, Series A, B, and C rounds. Their Founders Fund, launched in 2014, targets angel investments (under $250,000) in tech-enabled healthcare services and SaaS. Typical first-round investments range from $250,000 to $3,000,000, with follow-ons potentially doubling the commitment. For the Boston Millennia Partners II fund, deal sizes were $5 million to $10 million, with follow-ons up to $15-20 million.
Common questions
Does BOSTON MILLENNIA PARTNERS invest at the Seed stage?
Yes. BOSTON MILLENNIA PARTNERS lists Seed, Series A, Series B, Series C+ and angel among the stages it invests in.
What check size does BOSTON MILLENNIA PARTNERS write?
BOSTON MILLENNIA PARTNERS writes $250K–$3M checks.
Where does BOSTON MILLENNIA PARTNERS invest?
BOSTON MILLENNIA PARTNERS invests in the US and Europe.